children are as vulnerable to the novel coronavirus as adults studies have shown that infection and transmission in children and adults are similar even though most children have asymptomatic or mild infection they are an important source of transmission to others severe infections and mortality have frequently been reported in young infants and children with comorbidities largely post 36 weeks of asymptomatic or symptomatic infection the incidence of multisystem inflammatory syndrome misc is a rare but lifethreatening complication of covid 19 infection which may rarely lead to long term coronary artery changesvaccination status in various countriesseveral countries have begun giving vaccines to children while others have commenced with clinical trials in children in india so far only the covaxin vaccine trials in children have been initiated for the age group of 12 to 16 years and recruitment for clinical trials for the age group 6 to 12 years and 2 to 6 years however it will take several months before this trial is completed the united states had in may 2021 approved the use of the pfizer biontech vaccine for children above 12 years of age germany poland canada uae italy singapore are the other countries that approved vaccination for those above 12 years of age the uae has begun vaccination trials with sinopharm in children aged 3 17 years whereas china has approved emergency use of the sinovac vaccine for children 3 17 years of ageconcerns about vaccinating childrenall the vaccines currently being used have obtained an emergency use authorization eua for vaccinating people covid19 cases are now on the decline and most cases reported in children are mild with the report of myocarditis in adolescents older than 16 years of age and young adults 16 30 1 million dose 1 week after the 2nd dose causal link not established many experts feel covid19 vaccines for children should be considered under bla biological license application and not eua so that the agency considers data from a year or two before approval all those who developed myocarditis have recovered quickly to treatment the centers for disease control and prevention cdc recommends the continuation of vaccination in those above 12 years of age as known as potential benefits of covid19 vaccination are considered to outweigh the riskswhat are the optionsmost countries are using the pfizer biontech covid 19 vaccine in children above 12 years of age 100 efficacy and robust antibody response study in 2260 covid adolescents 1171 were vaccinated the same dose as for adults 2 doses 21 days apart and 1089 were not none of the vaccinated developed disease while out of the 1089 unvaccinated adolescents 16 developed covid19 this mrna vaccine therefore had good efficacy and a safety profile in children consistent with the adult studies the moderna trials in 6500 adolescents are in the final phase adult dose 2 doses 28 days apart in china the sinovac vaccine is being used for 3 years of age and aboveso far the world